1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
St.Shine Optical Co., Ltd.

St.Shine Optical Co., Ltd.

TTPEX:1565
90.60
TWD
-0.30
(-0.33%)
5.85EPS
16.50P/E
4.92BMarket Cap
Nov 04Next Earn
St.Shine Optical Co., Ltd.
TPEX:1565
(Taipei Exchange)

Recent

price

90.60

P/E

ratio

16.50

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
61.47
68.6
82.68
103.58
107.33
116.24
128.1
127.3
132.42
125.88
99.3
107.14
99.24
87.15
90.25
81.66
75.03
Revenue per Share
17.3
21.16
23.96
31.7
31.2
28.88
35.26
31.52
33.07
25.53
14.78
18.8
20.21
10.83
14.82
9.03
5.92
Basic EPS, GAAP
3.8
17.11
11.71
22.94
27.3
38.88
46.75
3.4
23.84
21.57
15.96
22.99
22.85
16.14
17.07
10.08
9.79
Free Cash Flow per Basic Share
10.5
14.5
15.5
17.5
22.5
23.85
23.5
27
25
26.5
18
12
15
13.5
7
9.5
- -
Dividend per Share
48.94
54.66
62.9
77.06
86.01
91.12
102.69
106.94
115.16
114.32
111.59
118.44
124.32
121.71
130.07
129.94
127.15
Book Value per Share
48.92
54.65
62.89
77.05
86.01
91.11
102.69
106.94
115.06
114.23
111.53
118.38
124.27
121.63
130
129.85
127.09
Tangible Book Value per Share
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
Basic Weighted Avg Shares
3,099
3,459
4,169
5,222
5,411
5,860
6,458
6,418
6,676
6,347
5,007
5,402
5,003
4,394
4,550
4,117
3,780
Sales/Revenue/Turnover
37.84
34.26
33.54
33.96
33.29
28.43
34.82
32.27
30.42
26.18
20.08
22.4
21.36
13.67
17.57
13.92
11.07
Operating Margin (%)
132
190
210
253
339
321
278
251
277
359
330
320
329
322
281
241
237
Depreciation Expense
872
1,067
1,208
1,598
1,573
1,456
1,778
1,589
1,668
1,287
745
948
1,019
546
747
455
298
Net Income, GAAP
17.56
12.3
12.22
13.29
15.47
15.23
17.43
19.13
20.31
20.28
20.84
17.85
20.45
19.58
20.74
21.16
22.48
Effective Tax Rate (%)
28.14
30.84
28.97
30.6
29.07
24.85
27.52
24.76
24.98
20.28
14.88
17.55
20.37
12.43
16.42
11.05
7.88
Profit Margin (%)
1,341
1,499
1,748
1,767
2,153
2,596
3,293
2,467
2,400
2,281
2,154
2,438
2,780
2,633
3,031
3,026
2,927
Working Capital
371
307
930
802
680
594
507
1,025
870
933
749
546
440
317
255
157
88
LT Debt
2,467
2,756
3,171
3,885
4,337
4,594
5,177
5,392
5,806
5,763
5,626
5,971
6,268
6,136
6,558
6,551
6,410
Total Equity
34.3
33.01
32.3
32.56
29.14
25.95
31.82
24.89
21.82
18.06
11
13.66
11.33
6.77
8.97
5.98
4.92
Return on Invested Capital (%)
32.55
34.92
32.84
35.11
31.38
27.74
31.69
24.52
23.6
18.34
10.73
13.31
14.06
7.9
10.85
6.55
4.47
Return on Capital (%)
37.99
40.85
40.76
45.3
38.27
32.61
36.39
30.07
29.78
22.25
13.08
16.34
16.65
8.8
11.77
6.94
4.71
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
272
242
259
LT Borrowings
85
63
40
LT Finance Leases
72
59
48
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
5,848
5,168
4,921

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,080
3,948
4,110
Cash, Cash Equivalents & STI
2,271
2,092
2,309
Accounts Receivable, Net
519
585
502
Inventories
1,203
1,199
1,229
Total Current Liabilities
1,054
1,118
1,183
Payables & Accruals
- -
- -
- -
ST Debt
272
242
259
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.72%
3.15%
-0.11%
Free Cash Flow
47.29%
-4.22%
-40.98%
Net Income, GAAP
-6.24%
-2.79%
-39.11%
Sales/Revenue/Turnover
-3.01%
-3.53%
-9.52%
Total Cash Common Dividend
-5.08%
-6.15%
35.71%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,100
996
1,224
1,230
4,550
2025
1,111
1,058
- -
942
4,117
2026
900
881
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.77
2.67
3.9
4.49
14.82
2025
3.43
0.57
- -
2.34
9.03
2026
1.39
1.61
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
7
2025
- -
- -
- -
- -
9.5
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
St.Shine Optical Co., Ltd. (1565.TWO) manufactures, sells, and trades contact lenses, optical lenses, and related products primarily for vision correction including myopia, hyperopia, and astigmatism; its core offerings encompass daily disposable soft contact lenses, frequent replacement lenses, color lenses, silicone hydrogel soft contact lenses, toric lenses, aberration control lenses, cast-molded soft contact lenses, and conventional lathe-cut lenses such as rigid gas permeable and soft variants, marketed under the Ticon brand while providing OEM, ODM, private label services, and consulting. Founded in 1981 as First Optical Co., Ltd. and rebranded in 1986, the company is headquartered in New Taipei City, Taiwan, with production facilities in Xizhi District, Keelung, and additional plants including Kang Ning, Asia-Pacific, Taiwan Science, Wudu, and Xike; it operates across Asia, Europe, North America, the Middle East, Japan, mainland China, Southeast Asia, and South America, holding certifications such as ISO 13485:2016, MDSAP, TFDA QMS, CE Marking, U.S. FDA 510(K), and approvals from regulatory bodies in Thailand, Vietnam, Indonesia, Malaysia, Australia, Singapore, Philippines, and Korea. Recent developments include new equity-method investments in affiliated companies during 2024, board changes with newly elected directors and independent directors effective June 2024, acquisition of property, plant, and equipment for NT$92.9 million alongside intangible assets, expansion of right-of-use assets through long-term factory leases, and sustained revenue growth to NT$4.55 billion in 2024 from strong operating performance.